Mobile

Cardamon: a trial of carfilzomib, cyclophosmamide & dexamethasone with maintenance carfilzomib in patients with symptomatic multiple myeloma eligible for transplant to evaluate the benefit of upfront ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-000506-35

Cardamon: a trial of carfilzomib, cyclophosmamide & dexamethasone with maintenance carfilzomib in patients with symptomatic multiple myeloma eligible for transplant to evaluate the benefit of upfront stem cell transplant

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The purpose of the CARDAMON study is: • To determine the efficacy of the triple regimen Carfilzomib, Cyclophosphamide and Dexamethasone (CarCyDex) as induction in untreated patients with symptomatic multiple myeloma (MM) who are candidates for autologous stem cell transplantation (ASCT). • To evaluate the benefit (progression free survival at 2 years) of upfront ASCT in patients achieving at least a partial response (PR) to induction with CarCyDex.

Critère d'inclusion

  • Multiple myeloma

Liens